Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
15/05/2026 12:35
May 15 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS ANNOUNCES NEW DATA FROM THE PHASE 2 TOIVA TRIAL OF QTORIN™ RAPAMYCIN IN CUTANEOUS VENOUS MALFORMATIONS PRESENTED AT THE 83RD ANNUAL MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY Source text: ID:nGNX31LRrJ Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs